In the commitment to safeguarding public health and enforcing strict regulatory standards, the Food and Drug Administration (FDA) has established Task Force Obsidian—a Technical Working Group (TWG) created to strengthen the FDA’s regulation of medical devices. In accordance with the provision of Republic Act No. 9711, Task Force Obsidian is set to reinforce the agency’s administrative and technical capacity to regulate health products and establishments within its jurisdiction.

Task Force Obsidian is tasked with developing clear and comprehensive policies and guidelines for the classification of medical devices submitted for FDA approval. This initiative aims to ensure that all devices are thoroughly and accurately classified according to their risk, use, and safety, thus fortifying the integrity of the FDA’s regulatory framework.

With transparency, efficiency, and accountability, the Task Force Obsidian will develop authoritative FDA issuances on device classification and streamline the application process. Task Force Obsidian will also thoroughly assess potential risks in the implementation of these policies and proactively recommend corrective measures to safeguard against non-compliance. Regular updates will be delivered directly to the Office of the Director General, ensuring top-level oversight and swift action on critical issues.

This bold step underscores the FDA’s relentless pursuit of excellence in regulating health products, as it continues to raise the bar for compliance and public safety. Task Force Obsidian is expected to play an important role in fortifying the agency’s regulatory authority and setting new benchmarks for the industry. The final issuance of its work will mark a major milestone in enhancing the FDA’s mission to protect the health and well-being of the public.